Protagonist Therapeutics Stock Performance
| PTGX Stock | USD 51.10 1.43 2.72% |
On a scale of 0 to 100, Protagonist Therapeutics holds a performance score of 7. The company holds a Beta of -1.46, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Protagonist Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Protagonist Therapeutics is expected to outperform it. Please check Protagonist Therapeutics' potential upside, as well as the relationship between the accumulation distribution and period momentum indicator , to make a quick decision on whether Protagonist Therapeutics' historical price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Protagonist Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady technical and fundamental indicators, Protagonist Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.23) | Five Day Return (2.12) | Year To Date Return 34.76 | Ten Year Return 348.97 | All Time Return 348.97 |
1 | Acquisition by Asif Ali of 12000 shares of Protagonist Therapeutics subject to Rule 16b-3 | 12/27/2024 |
2 | Acquisition by Asif Ali of 38520 shares of Protagonist Therapeutics at 38.98 subject to Rule 16b-3 | 01/02/2025 |
3 | Disposition of 12636 shares by Dinesh Patel of Protagonist Therapeutics subject to Rule 16b-3 | 01/15/2025 |
4 | Disposition of 3252 shares by Molina Arturo Md of Protagonist Therapeutics subject to Rule 16b-3 | 01/16/2025 |
5 | Disposition of 5359 shares by Dinesh Patel of Protagonist Therapeutics at 38.18 subject to Rule 16b-3 | 02/19/2025 |
6 | Can This Biopharma Innovator Revolutionize Blood Disorder Treatment | 02/26/2025 |
7 | Disposition of 24000 shares by Dinesh Patel of Protagonist Therapeutics at 4.21 subject to Rule 16b-3 | 02/28/2025 |
8 | Protagonist Therapeutics Given New 57.00 Price Target at JPMorgan Chase Co. | 03/04/2025 |
9 | Why Protagonist Therapeutics, Inc. Went Up on Monday | 03/11/2025 |
10 | Protagonist Therapeutics Upgraded to Buy Heres Why | 03/12/2025 |
11 | Disposition of 2077 shares by Molina Arturo Md of Protagonist Therapeutics at 38.98 subject to Rule 16b-3 | 03/13/2025 |
12 | The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and JJ | 03/14/2025 |
13 | Disposition of 4000 shares by Waddill William D. of Protagonist Therapeutics at 54.25 subject to Rule 16b-3 | 03/17/2025 |
14 | Analysts Mentions Growth Catalysts for Protagonist Therapeutics Best Biotech Stock for 2025 | 03/18/2025 |
15 | Insider Sell William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc | 03/21/2025 |
| Begin Period Cash Flow | 187 M |
Protagonist |
Protagonist Therapeutics Relative Risk vs. Return Landscape
If you would invest 3,951 in Protagonist Therapeutics on December 25, 2024 and sell it today you would earn a total of 1,154 from holding Protagonist Therapeutics or generate 29.21% return on investment over 90 days. Protagonist Therapeutics is currently generating 0.594% in daily expected returns and assumes 6.4584% risk (volatility on return distribution) over the 90 days horizon. In different words, 57% of stocks are less volatile than Protagonist, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protagonist Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protagonist Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protagonist Therapeutics, and traders can use it to determine the average amount a Protagonist Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.092
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PTGX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.46 actual daily | 57 57% of assets are less volatile |
Expected Return
| 0.59 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Protagonist Therapeutics is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protagonist Therapeutics by adding it to a well-diversified portfolio.
Protagonist Therapeutics Fundamentals Growth
Protagonist Stock prices reflect investors' perceptions of the future prospects and financial health of Protagonist Therapeutics, and Protagonist Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protagonist Stock performance.
| Return On Equity | 0.54 | ||||
| Return On Asset | 0.29 | ||||
| Profit Margin | 0.63 % | ||||
| Operating Margin | 0.74 % | ||||
| Current Valuation | 2.82 B | ||||
| Shares Outstanding | 61.38 M | ||||
| Price To Earning | (4.81) X | ||||
| Price To Book | 4.78 X | ||||
| Price To Sales | 7.44 X | ||||
| Revenue | 434.43 M | ||||
| Gross Profit | 434.43 M | ||||
| EBITDA | 252.84 M | ||||
| Net Income | 275.19 M | ||||
| Cash And Equivalents | 291.89 M | ||||
| Cash Per Share | 5.95 X | ||||
| Total Debt | 10.87 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 7.59 X | ||||
| Book Value Per Share | 11.06 X | ||||
| Cash Flow From Operations | 184.15 M | ||||
| Earnings Per Share | 4.23 X | ||||
| Market Capitalization | 3.23 B | ||||
| Total Asset | 744.73 M | ||||
| Retained Earnings | (340.52 M) | ||||
| Working Capital | 544.24 M | ||||
| Current Asset | 83.24 M | ||||
| Current Liabilities | 6.43 M | ||||
About Protagonist Therapeutics Performance
Evaluating Protagonist Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Protagonist Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protagonist Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (29.92) | (31.42) | |
| Return On Tangible Assets | 0.37 | 0.39 | |
| Return On Capital Employed | 0.36 | 0.38 | |
| Return On Assets | 0.37 | 0.39 | |
| Return On Equity | 0.41 | 0.43 |
Things to note about Protagonist Therapeutics performance evaluation
Checking the ongoing alerts about Protagonist Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protagonist Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protagonist Therapeutics is way too risky over 90 days horizon | |
| Protagonist Therapeutics appears to be risky and price may revert if volatility continues | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Insider Sell William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc |
- Analyzing Protagonist Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protagonist Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protagonist Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protagonist Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protagonist Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protagonist Therapeutics' stock. These opinions can provide insight into Protagonist Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.